Spillover Effects of Benefit Expansions and Carve-Outs on Psychotropic Medication Use and Costs
| Autor: | Agnes Rupp, Grayson S. Norquist, Samuel H. Zuvekas |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Specialty 0603 philosophy ethics and religion Behavioral Medicine 03 medical and health sciences Catchment Area Health Spillover effect Health care Humans Medicine Medical prescription Pharmaceutical innovations Psychiatry Psychotropic Drugs business.industry lcsh:Public aspects of medicine 030503 health policy & services Health Policy Managed Care Programs Disease Management lcsh:RA1-1270 06 humanities and the arts Middle Aged medicine.disease Mental health Drug Utilization Substance abuse Organizational Case Studies 060302 philosophy Female 0305 other medical science business Panel data |
| Zdroj: | Inquiry: The Journal of Health Care Organization, Provision, and Financing, Vol 42 (2005) |
| ISSN: | 1945-7243 0046-9580 |
| DOI: | 10.5034/inquiryjrnl_42.1.86 |
| Popis: | This paper extends the previous literature examining the impacts of managed behavioral health care carve-outs and mental health parity mandates on mental health and substance abuse (MH/SA) specialty treatment use and costs by considering the effects on psychotropic prescription medication costs. We use multivariate panel data methods to remove underlying secular growth trends, driven by increased demand for improved MH/SA treatment related to pharmaceutical innovations. We find that psychotropic medication costs continued to increase after the introduction of a substantial benefit expansion and carve-out to a managed behavioral health organization (MBHO), offsetting large declines in inpatient specialty MH/SA costs. However, we find evidence that the MBHO may have restrained growth in prescription medication spending. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|